# Study to Assess Potential Different Properties of Telmisartan Compared to Candesartan in Healthy Volunteers

> **NCT02261116** · PHASE4 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 24 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Telmisartan
- **DRUG:** Candesartan
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02261116
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-04
- **Primary completion:** 2002-08
- **Final completion:** —
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2014-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02261116

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02261116, "Study to Assess Potential Different Properties of Telmisartan Compared to Candesartan in Healthy Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02261116. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*